Anthropic earns warrants on a third of a percent of Akamai for every extra $1 billion it spends

Crypto Briefing puts the full stake at roughly $857 million "in potential equity value at the exercise price alone" ^[9]. The figure is 7.7 million shares multiplied by the $111.33 strike ^[1], so it measures the cash Anthropic would pay Akamai to exercise. Anthropic's gain is a different number: the gap between Akamai's market price and $111.33 on each vested share. Neither report gives Akamai's share price, so the warrant's current value cannot be calculated from them.

The vesting schedule is easier to price. The tranche that vests on the commitment is about 3.08 million shares, and the tranche tied to new spending is about 4.62 million ^[2]. Spread over up to $9 billion of extra spend ^[5], each additional $1 billion unlocks a third of a percentage point of Akamai, or rather options on it, about 513,000 shares (4.62 million divided by nine) ^[3]. Exercising that slice would cost Anthropic about $57 million ^[4]. For every $10 that Akamai trades above the strike, the same slice is worth about $5 million to Anthropic, roughly half a percent of the $1 billion it spent ^[5].

Crypto Briefing's totals do not add up. It says the $11.6 billion deal and a $1.8 billion contract from May together put the relationship at roughly $20 billion ^[3], but those two sum to $13.4 billion ^[7]. Elsewhere it calls $20 billion the upside of the seven-year deal alone ^[13], a figure that fits $11.6 billion plus the $9 billion that vests the 3%, or $20.6 billion ^[7]. If the May contract counts toward the $9 billion, Anthropic needs fewer new dollars to reach full vesting.

Three outcomes follow from the terms. Below $111.33, the warrant has no exercise value and holders keep their share of the company intact. Above the strike, with Anthropic spending only the committed $11.6 billion, about 3.08 million shares are in play ^[2]. At full spend and full exercise, holders take 7.7 million new shares ^[4] and Akamai collects about $857 million in cash ^[1].

I think the warrant is a volume rebate paid in Akamai options, and existing holders fund it. The case against, which Crypto Briefing makes, is that 5% dilution is a reasonable price for a customer that could become a significant share of revenue ^[12]. The figures give that case weight: $11.6 billion over seven years is about $1.66 billion a year ^[6], against annual revenue that has historically sat in the low single-digit billions ^[7]. Timing is where the two views separate. Akamai recognises revenue only as capacity is activated ^[6], while the first 2% vests on the commitment itself ^[5]. If Anthropic revenue reaches about $1.66 billion a year early in the term, the counter-case holds. If activation lags, holders carry the first tranche with little revenue behind it.

Anthropic, valued near $965 billion according to Crypto Briefing ^[11], would spend about 0.09% of that figure to exercise the whole warrant ^[8]. To Akamai the same shares are 5% of the company, though non-voting, so governance stays with Akamai's board ^[10]. Amazon's arrangement ran the other way, with AWS investing billions directly into Anthropic ^[8]. Here the supplier offers the lab an option on the supplier's own equity. One deal between one lab and one supplier does not show that AI labs in general now pay for compute this way.